جست‌وجوی استاد و پژوهشگر

• Cognitive Neurology
• Neural Data Science
• Statistical Computing
• +۵ مورد دیگر

Professor Karsten Mueller is a distinguished researcher in cognitive neurology and neural data science at the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig, Germany. He holds the position of Associate Professor at Leipzig University's Faculty of Medicine and serves as a faculty member at both the International Max Planck Research School on Neuroscience of Communication (IMPRS NeuroCom) and the International Max Planck Research School on Cognitive NeuroImaging (IMPRS CoNI). Additionally, he has been appointed as a Visiting Professor at the First Faculty of Medicine at Charles University in Prague since 2025. His work focuses on advanced neuroimaging techniques to understand brain structure and function in various neurological conditions. Dr. Mueller received his Dr. habil. degree in Cognitive Neurology from Leipzig University's Faculty of Medicine in 2006, the same year he became a Private lecturer (Privatdozent) at the institution. His academic journey includes a postdoctoral position from 1999 to 2008 at the Department of Cognitive Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, under the supervision of D.Y. von Cramon. In 2015, he was awarded the title of Apl.-Professor (Associate Professor) at Leipzig University, recognizing his significant contributions to the field. Professor Mueller's research spans several critical areas in cognitive neuroscience and neuroimaging. His primary focus is on understanding brain connectivity and structure in neurological disorders, particularly Parkinson's disease, frontotemporal dementia, and the effects of deep brain stimulation. He leads the Methods and Development Group for Neural Data Science and Statistical Computing, where his team develops advanced computational approaches for analyzing complex neuroimaging data. His work bridges clinical neurology with cutting-edge data science, creating innovative methods to extract meaningful insights from brain imaging studies. This interdisciplinary approach has led to significant contributions in understanding how neurological conditions affect brain networks and cognitive functions. Analysis of Professor Mueller's recent publication record reveals a strong emphasis on applying advanced computational and machine learning techniques to neuroimaging data. His research consistently explores the relationship between brain structure/function and various neurological conditions, with particular attention to Parkinson's disease, frontotemporal dementia, and stroke recovery. A notable trend is his increasing use of artificial intelligence and deep learning approaches to improve diagnostic accuracy and understand disease progression. His work also demonstrates a growing interest in connecting peripheral biomarkers (like retinal imaging) with central nervous system changes, suggesting a more holistic approach to understanding neurological disorders. The collaborative nature of his research is evident through numerous international partnerships, particularly with institutions in Prague. Professor Mueller leads the Methods and Development Group for Neural Data Science and Statistical Computing at the Max Planck Institute. This team focuses on developing innovative computational approaches for analyzing complex neuroimaging datasets. Their work encompasses statistical modeling, machine learning applications, and the creation of open-source tools for the neuroscience community. The group collaborates extensively with clinical researchers to translate advanced data analysis techniques into meaningful clinical insights, particularly in the areas of movement disorders, dementia, and brain connectivity research.

Goncalo Abecasisمشاهده پروفایل

استاد

• Statistical Genetics
• Human Genetics
• Biostatistics
• +۵ مورد دیگر

Goncalo Abecasis is the Felix E. Moore Collegiate Professor of Biostatistics at the University of Michigan School of Public Health, where he leads the Center for Statistical Genetics. He received his DPhil in Human Genetics from the University of Oxford in 2001 and joined the University of Michigan faculty that same year. His research focuses on developing statistical and computational tools for identifying genetic variants associated with human disease and variation. His research interests include the development of analytical methods for mapping complex traits, utilization of linkage disequilibrium in gene mapping, quantitative trait analysis, and characterization of human genetic variation. He has pioneered computational approaches that enable the analysis of large genomic datasets generated by high-throughput technologies. His work addresses practical challenges in handling real-world genetic data, including genotype error detection and relationship verification. Abecasis has developed numerous widely-used software tools including Merlin (for pedigree analysis), MACH (for haplotype estimation), LAMP (for association testing), QTDT (for quantitative trait analysis), GOLD (for linkage disequilibrium visualization), and GRR (for relationship error detection). His publications span statistical genetics methodology, software development, and applications to diseases including diabetes, glaucoma, age-related macular degeneration, schizophrenia, and aging-related traits. His recent work involves large-scale genome-wide association studies with hundreds of thousands of participants, focusing on complex traits related to substance use, cardiovascular health, metabolic disorders, and eye diseases. The computational tools he develops are used in hundreds of gene-mapping projects worldwide. Abecasis collaborates extensively with researchers studying diabetes (Dr. Michael Boehnke), eye diseases (Drs. Julia Richard and Anand Swaroop), schizophrenia (Dr. Maria Karayiorgou), and aging-related traits (Dr. David Schlessinger).

Joseph Caprioliمشاهده پروفایل

استاد

• Glaucoma
• Optic Nerve Imaging
• Retinal Neurodegeneration
• +۵ مورد دیگر

Joseph Caprioli is a distinguished Professor of Ophthalmology at the Jules Stein Eye Institute , University of California, Los Angeles . He serves as the David May II Professor and Chair, Chief of Glaucoma, and Director of the Glaucoma Photography Laboratory. His research focuses on glaucoma progression, retinal imaging, intraocular pressure dynamics, and machine learning applications in ophthalmic diagnostics. Key Research Areas : Glaucoma, optic nerve imaging, retinal neurodegeneration, OCT technology, visual field analysis Labs/Teams : Glaucoma Photography Laboratory, Ophthalmology Diagnostic Laboratory Perimetry Laboratory Recent publications highlight his work on deep learning models for optic disc analysis (e.g., DDLSNet, RimNet), blood pressure correlations with retinal thinning , and structural-functional progression trajectories in glaucoma. His studies often integrate Bayesian hierarchical modeling and neural networks to enhance diagnostic accuracy. He actively investigates telemedicine applications in glaucoma care and long-term surgical outcomes (e.g., Ahmed valve revisions, trabeculectomy with Mitomycin C). His work bridges clinical practice with computational advances to improve glaucoma management.

• Animal physiological chemistry
• Physiology
• Behavioral biology
• +۵ مورد دیگر

Toshiyuki Okano is a Professor at Waseda University's Faculty of Science and Engineering, School of Advanced Science and Engineering. He holds a Ph.D. in Science from Kyoto University and maintains an active research program focused on circadian biology, photobiology, and magnetoreception. His work bridges molecular biology, physiology, and behavioral studies across diverse animal models including zebrafish, medaka, and other teleost species. Dr. Okano received his education at Kyoto University, completing his undergraduate studies from 1984-1988 and his graduate studies from 1988-1993. His academic journey includes positions at The University of Tokyo (1993-2011), Japan Science and Technology Agency (2001-2010), and Waseda University (2007-present). His research interests span multiple interconnected fields of chronobiology and photobiology. Dr. Okano investigates how animals detect and respond to environmental light cues through specialized photoreceptive molecules like cryptochromes. His work explores circadian rhythms, lunar-synchronized behaviors, magnetoreception mechanisms, and the molecular basis of photoperiodic time measurement. He has made significant contributions to understanding how cryptochrome proteins function as potential magnetoreceptors in birds and as circadian clock components across diverse species. Dr. Okano's publication record demonstrates consistent productivity with 74 papers and 3,592 citations as of 2025, reflecting an h-index of 34. His research has evolved from foundational studies on pineal photoreception in birds to more recent work examining lunar rhythms, magnetoreception, and innovative biotechnological applications like the THETA protein purification system. His interdisciplinary approach combines molecular biology, biochemistry, and behavioral analysis across multiple animal models. Among his notable scientific achievements are: New Investigator Award from the American Society for Photobiology (2002) Yoshida Encouragement Award from the Japanese Society for Comparative Physiology and Biochemistry (1995) Dr. Okano serves in leadership roles within several professional societies, including as Councilor for the Quantum Life Science Society and Secretary for the Japanese Society of Comparative Physiology and Biochemistry. His laboratory maintains active collaborations with researchers at The University of Tokyo, Kyoto University, and other institutions, focusing on the molecular mechanisms of biological timing systems. Current research directions include exploring the relationship between circadian and circalunar timing mechanisms, developing novel biotechnological tools based on light-sensitive proteins, and investigating the evolutionary adaptations of visual systems in deep-sea organisms.

• Autophagy
• Functional Foods
• Neurodegenerative Diseases
• +۳ مورد دیگر

Taichi Hara is a Professor at the Faculty of Human Sciences, Waseda University since 2017. Previously held positions at Gunma University (2010-2017) and the University of Pennsylvania (2009-2010). His research bridges autophagy , functional foods , and protein quality control in neurodegenerative diseases. Education: Ph.D. in Medicine from Kyushu University (2004). Research Themes focus on autophagy regulation by dietary compounds, mechanisms of protein accumulation in Charcot-Marie-Tooth disease and tauopathy, and applications of mTOR signaling in healthspan extension. His work connects food science with cellular degradation pathways and neurodegenerative disease modeling. Article Trends emphasize plant-derived compounds (isorhamnetin, bilberry anthocyanins) for autophagy modulation, mTORC2-GATA3 axis in lysosomal function, and mouse models for neurodegenerative disorders. Studies span hepatocyte protection , skin aging , and embryonic development . Professional Memberships include the Japanese Society for Food Science and Technology, Japanese Biochemical Society, and Japanese Society for Neurochemistry.

Pleasantine Millمشاهده پروفایل

استاد

• Genetics of Cilia Biology
• Ciliopathies
• Developmental genetics
• +۸ مورد دیگر

Professor Pleasantine Mill is a leading researcher at the University of Edinburgh, serving as Group Leader within the MRC Human Genetics Unit at the Institute of Genetics and Cancer. She received her BSc in Microbiology and Immunology from McGill University and completed her PhD in Medical and Molecular Genetics at the University of Toronto, where she studied Gli transcription factors in Hedgehog signaling using mouse models. Her research focuses on the genetics of cilia biology , investigating how defects in these specialized cellular structures lead to developmental disorders and postnatal health issues collectively known as ciliopathies. Professor Mill employs a multidisciplinary approach combining genetic screens, human disease genetics, advanced imaging techniques, and therapeutic genome editing to address fundamental questions about cilia assembly, function, and potential treatments for ciliopathies. Professor Mill's publication record demonstrates consistent high-impact research, with recent papers in Science (2024), eLife (2021), and Developmental Cell (2018). Her work spans multiple subfields including ciliary microtubule dynamics, dynein assembly mechanisms, cilia-cell cycle relationships, and therapeutic applications of genome editing for ciliopathies. The research shows an evolving trajectory from basic cilia genetics toward translational applications and advanced imaging approaches. Scientific recognition: Canadian NSERC Post-doctoral Fellowship Caledonian Research Fellowship Multiple major research grants including MRC, European Commission, and LifeArc funding Extensive media coverage of her research including The Times, The Sun, and international outlets Professor Mill actively supervises PhD students and postdoctoral researchers, with current projects spanning precision medicine, macular research, and AI-integrated cilia studies. Her lab maintains strong clinical collaborations and participates in national networks focused on rare diseases. The research group benefits from substantial funding through multiple active projects with the Medical Research Council, European Commission, and other major funders, enabling cutting-edge research in cilia biology and its implications for human health. The Mill Lab focuses on four interconnected research strands: genetic screens to dissect ciliary complexity, human disease genetics to identify ciliopathy alleles, advanced imaging techniques to visualize dynamic ciliary structures, and therapeutic genome editing approaches to potentially correct ciliopathies. This integrated approach positions the lab at the forefront of cilia research with significant potential for clinical translation.

John Spudichمشاهده پروفایل

استاد

• Light sensors and photosensory transduction
• Microbial rhodopsins
• Membrane receptor structure/function
• +۴ مورد دیگر

John Spudich, PhD is a Professor and Director of the Center for Membrane Biology at The University of Texas Health Science Center at Houston, where he holds the prestigious Robert A. Welch Distinguished Chair in Chemistry. His academic appointments span the Molecular and Translational Biology and Neurosciences Graduate Programs, reflecting the interdisciplinary nature of his work. Dr. Spudich's research focuses on microbial sensory rhodopsins, particularly their molecular mechanisms and applications as molecular tools for research and gene therapy. His laboratory made the groundbreaking discovery of natural light-gated anion channels (ACRs), which has opened new pathways for neural inhibition in both research and clinical applications. His work bridges fundamental biophysics with translational medicine, with applications ranging from vision restoration to neurological disorder treatments. His publication record demonstrates consistent high-impact contributions to the field, with key publications in Science, PNAS, and Annual Review of Biochemistry. These works have established foundational knowledge in microbial rhodopsin diversity, mechanisms, and optogenetic applications. Robert A. Welch Distinguished Chair - A prestigious endowed position recognizing exceptional contributions to chemistry Fellow of the American Academy of Arts and Sciences - Election to one of America's oldest and most prestigious honorary societies President of the International Union of Photobiology - Leadership role in advancing research on light's role in biology and photomedicine Dr. Spudich actively translates basic research into clinical applications, with his work on anion channelrhodopsins directly informing ongoing clinical trials for vision restoration and potential treatments for neurological disorders. His laboratory implements photochemistry, structural biology, and biophysical methods to elucidate atomic structure/function relationships in sensory rhodopsin activation, while developing methods for studying their function in animal cells and purified systems.

• Protein Structure
• Nuclear Receptor Signaling
• Drug Discovery
• +۷ مورد دیگر

Patrick Griffin is a Professor and Scientific Director at The Scripps Research Institute (TSRI) Scripps Florida, where he serves in the Department of Molecular Therapeutics. With over 25 years of experience in drug discovery and development, Dr. Griffin has established himself as a leading researcher in protein structure and nuclear receptor signaling. His career spans both industry and academia, with significant contributions to pharmaceutical development including key work on Januvia (a DPP4 inhibitor now in clinical use). Ph.D. in Chemistry from the University of Virginia under Professor Donald F. Hunt Postdoctoral Fellowship with Professor Leroy Hood at Caltech Former Chief Science Officer at ExSAR Corporation Former Senior Director of Chemistry at Merck Research Laboratories Dr. Griffin's research program focuses on understanding nuclear receptor (NR) signaling using structural, chemical and biological approaches. His laboratory has made significant contributions to understanding the mechanism of ligand activation of NRs such as PPARs, RORs, REV-ERBs, LRH1, VDR, ER, GR, and PR. Through the use of mutagenesis, HDX-MS, crystallography, proteomics and genomics, his team studies the structure-function relationships of nuclear receptors, enzymes, and G protein coupled receptors (GPCRs). A major emphasis of his chemical biology program is developing functionally selective and promoter-specific modulators targeting diseases such as cancer, autoimmune disorders, obesity, and diabetes. Dr. Griffin's lab is particularly well-known for developing and applying biophysical methods including HDX and XL-MS platforms for analyzing protein plasticity, with a focus on nuclear receptors, enzymes, and GPCRs. Dr. Griffin's recent publications (2022-2025) demonstrate continued innovation in structural proteomics, nuclear receptor biology, and therapeutic development. His work shows a clear trajectory from fundamental protein structure research toward translational applications, particularly in metabolic disorders, cancer, and neurological conditions. A significant theme across his recent work is the development of non-muscle myosin II inhibitors with therapeutic potential, reflecting his long-standing interest in protein structure-function relationships and their therapeutic modulation. His research continues to bridge structural biology, chemical biology, and drug discovery, with particular emphasis on nuclear receptor signaling pathways and their role in metabolic regulation. Dr. Griffin's research impact is evidenced by his publication record of over 240 peer-reviewed manuscripts, an h-index of 83 (58 since 2016), and an i10-index of 223 according to Google Scholar. Dr. Griffin has served as PI, Co-PI, and co-investigator on numerous NIH-funded grants. Notable funding includes leadership of "The Comprehensive Center for Chemical Probe Discovery and Optimization at Scripps," a 6-year U54 MLPCN Roadmap initiative. He co-founded Ember, a biotech company funded by Third Rock Ventures, based on work from a RC4 collaboration with Bruce Spiegelman at Dana Faber. Dr. Griffin has maintained a 13-year collaboration with Eli Lilly and serves as PI on grants with private biotechs including Synkine Therapeutics. As Co-PI on a NIH Blueprint UH3 grant, he co-founded Myosin Therapeutics, whose clinical candidate emerged from this NIH-funded program. Dr. Griffin leads a research program that integrates structural biology, chemical biology, and drug discovery approaches. His laboratory has developed advanced HDX-MS and XL-MS platforms for protein structure analysis. The team's work spans from fundamental protein structure studies to translational drug discovery, with particular expertise in nuclear receptor biology. His lab has made significant contributions to understanding nuclear receptor signaling mechanisms and developing novel therapeutic approaches targeting these pathways.

• Protein Structure
• Nuclear Receptors
• Drug Discovery
• +۵ مورد دیگر

Patrick Griffin is Professor and former Chair of the Department of Molecular Therapeutics at The Scripps Research Institute, with over 25 years of experience in protein structure research and drug discovery. His career spans both industry and academia, with significant contributions to structural proteomics and nuclear receptor pharmacology. Dr. Griffin earned his Ph.D. in Chemistry from the University of Virginia under Professor Donald F. Hunt, where he contributed to groundbreaking work in protein sequencing using tandem mass spectrometry. He completed postdoctoral training with Professor Leroy Hood at Caltech before holding leadership positions at Merck Research Laboratories and ExSAR Corporation. His research program focuses on protein structure-function relationships, particularly mutational- and ligand-mediated alterations in protein structural plasticity. Using mutagenesis, HDX-MS, crystallography, proteomics and genomics, his laboratory investigates nuclear receptors (PPARs, RORs, REV-ERBs, LRH1, VDR), enzymes, and GPCRs. The lab has made significant contributions to understanding ligand activation mechanisms and developing functionally selective modulators for diseases including cancer, autoimmune disorders, obesity, and diabetes. Analysis of Dr. Griffin's recent publications reveals a strong emphasis on nuclear receptor structural biology, particularly PPAR family members, with increasing integration of structural proteomics techniques to study therapeutic targets. His work shows a clear trajectory from basic structural understanding to therapeutic applications, with multiple discoveries translated into clinical candidates. Dr. Griffin serves as PI or Co-PI on multiple NIH-funded projects including a U54 MLPCN Roadmap initiative, RC4 programs, and U19 NCDDDG grants. He maintains a 13-year collaboration with Eli Lilly and has co-founded biotech companies including Ember and Myosin Therapeutics based on his research findings. His laboratory has developed advanced biophysical methods, particularly in HDX and XL-MS platforms for analyzing protein plasticity. The research group operates at the intersection of structural biology, chemical biology, and translational medicine, with strong industry partnerships facilitating the translation of basic discoveries into therapeutic candidates.

Andrew F.X. Goldbergمشاهده پروفایل

استاد

• Retinal Degenerative Diseases
• Photoreceptor Biology
• Inherited Retinal Diseases
• +۳ مورد دیگر

Andrew F.X. Goldberg serves as the Reddy Professor of Biomedical Sciences at the Eye Research Institute within Oakland University's William Beaumont School of Medicine. His research targets retinal degenerative diseases affecting over 2 million Americans, focusing on photoreceptor structure and function to develop therapies for inherited vision loss. Education: B.S. in Biochemistry/Philosophy from Binghamton University (1985) Ph.D. in Biochemistry from Brandeis University (1992) Postdoctoral training in Photoreceptor structure at University of British Columbia (1997) Postdoctoral training in Photoreceptor function at University of Washington (1998) Dr. Goldberg's laboratory employs biochemical, biophysical, and molecular genetic techniques across in vitro, in cellulo, and in vivo models to dissect how genetic defects compromise rod and cone photoreceptor architecture. His work bridges fundamental neuroscience with clinical ophthalmology, emphasizing translational pathways from molecular mechanisms to therapeutic interventions for conditions like retinitis pigmentosa. The research program maintains strong interdisciplinary connections between biochemistry, neural tissue specialization, and vision science. He secures funding from major organizations including the National Science Foundation, National Eye Institute, Foundation Fighting Blindness, The Grass Foundation, E. Matilda Zeigler Foundation, Research Excellence Fund (Oakland University), and Mid-West Eyebanks. Professional affiliations: Association for Research in Vision and Ophthalmology (ARVO) American Society for Biochemistry and Molecular Biology (ASBMB) Society for Neuroscience (SfN) Biophysical Society Dr. Goldberg leads the Goldberg Laboratory with a mission to elucidate the molecular basis of photoreceptor cellular structure, establishing rational foundations for designing novel therapies against blinding retinal degenerations. The lab emphasizes the critical relationship between retinal photoreceptor biology and human vision preservation.